Masoud H Manjili

US Patent:

7378096, May 27, 2008

Filed:

Jun 3, 2002

Appl. No.:

10/161028

Inventors:

John R. Subjeck - Williamsville NY, US
Robert A. Henderson - Seattle WA, US
Elizabeth A. Repasky - Williamsville NY, US
Latif Kazim - Amherst NY, US
Xiang-Yang Wang - Buffalo NY, US
Masoud H. Manjili - Williamsville NY, US

International Classification:

A61K 39/00
A61K 47/42
A61K 46/42

US Classification:

4241841, 4241921, 42419511, 4242661, 4242781, 4241931, 514 21

Abstract:

Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

US Patent:

8080388, Dec 20, 2011

Filed:

May 27, 2008

Appl. No.:

12/127499

Inventors:

John R. Subjeck - Williamsville NY, US
Robert A. Henderson - Seattle WA, US
Elizabeth A. Repasky - Williamsville NY, US
Latif Kazim - Amherst NY, US
Xiang-Yang Wang - Buffalo NY, US
Masoud H. Manjili - Williamsville NY, US

Assignee:

Health Research, Inc. - Buffalo NY

International Classification:

C12N 15/09
C12N 5/07
C12N 5/09
C12N 5/10

US Classification:

435 691, 4352523, 435325

Abstract:

Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

US Patent:

20070243209, Oct 18, 2007

Filed:

Oct 28, 2006

Appl. No.:

11/554022

Inventors:

Brahm Segal - Williamsville NY, US
Masoud Manjili - Richmond VA, US
John Subjeck - Wiliamsville NY, US

Assignee:

HEALTH RESEARCH, INC. - Buffalo NY

International Classification:

A61K 39/385
A61K 31/711
A61K 48/00
A61P 37/00
C07H 21/04
C07K 4/06
C12N 5/06

US Classification:

424193100, 424274100, 424275100, 424093210, 435372000, 514044000, 530403000, 536023400

Abstract:

The present invention relates to various pharmaceutical compositions that can be used as active or passive vaccines for the treatment or prevention of fungal disease. Methods for prevention and treatment of infectious and allergic fungal diseases in subjects using the pharmaceutical compositions of the present invention are also disclosed.

US Patent:

20110034347, Feb 10, 2011

Filed:

Aug 20, 2010

Appl. No.:

12/859933

Inventors:

Masoud Manjili - Richmond VA, US
Maciej Kmieciak - Richmond VA, US
Harry D. Bear - Richmond VA, US
Catherine I. Dumur - Richmond VA, US
Michael O. Idowu - Richmond VA, US

International Classification:

C40B 30/04
C12Q 1/68
C12M 1/34
C40B 40/06
C40B 60/12

US Classification:

506 9, 435 6, 4352872, 506 16, 506 39

Abstract:

Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols.

US Patent:

20130309213, Nov 21, 2013

Filed:

May 5, 2011

Appl. No.:

13/877536

Inventors:

Masoud H. Manjili - Richmond VA, US
Harry D. Bear - Richmond VA, US
Maciej Kmieciak - Richmond VA, US

Assignee:

VIRGINIA COMMONWEALTH UNIVERSITY - Richmond VA

International Classification:

C12N 5/0783
C12N 5/0784

US Classification:

424 9371, 435375, 435377

Abstract:

Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.